| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $184.1K | 0.00% | 39.60K | −81% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a XGN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Black Jeffrey GChief Financial Officer | Stock Award(Grant) at price 7.12 per share. | 1.6K | $11.19K |
| Aug 31, 2026 | Black Jeffrey GChief Financial Officer | Sale at price 7.22 per share. | 20.6K | $148.78K |
| Mar 11, 2026 | Black Jeffrey GChief Financial Officer | Stock Award(Grant) at price 3.08 - 3.16 per share. | 76.5K | $241.65K |
| Mar 11, 2026 | Aballi JohnChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Mar 2, 2026 | Aballi JohnChief Executive Officer | Stock Award(Grant) at price 3.08 per share. | 2.5K | $7.80K |
| Mar 2, 2026 | Aballi JohnChief Executive Officer | Sale at price 3.62 per share. | 15.7K | $56.83K |
| Feb 23, 2026 | Black Jeffrey GChief Financial Officer | Sale at price 3.61 per share. | 1.6K | $5.72K |
| Feb 23, 2026 | Aballi JohnChief Executive Officer | Sale at price 3.61 per share. | 11.4K | $41.26K |
| Oct 15, 2025 | Aballi JohnChief Executive Officer | Sale at price 11.82 per share. | 31.8K | $375.60K |
| Sep 1, 2025 | Black Jeffrey GChief Financial Officer | Sale at price 9.79 per share. | 20.5K | $200.36K |
| Mar 24, 2025 | Nmsic Co-Investment Fund, L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 3.30 per share. | 350K | $1.16M |
| Feb 27, 2025 | Aballi JohnChief Executive Officer | Stock Award(Grant) at price 3.46 per share. | 8.6K | $29.83K |
| Feb 20, 2025 | Black Jeffrey GChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Feb 20, 2025 | Aballi JohnChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 112.5K | — |
| Nov 19, 2024 | Nmsic Co-Investment Fund, L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 4.20 per share. | 200K | $840.00K |
| Nov 14, 2024 | Black Jeffrey GChief Financial Officer | Purchase at price 2.98 per share. | 22.3K | $66.45K |
| Nov 13, 2024 | Aballi JohnChief Executive Officer | Purchase at price 2.81 per share. | 24.3K | $68.30K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -39.5 | -1.6 | -17.1 | -3.3 | 71.7 | -6.6 | -2.6 | 62.0 | 10.8 | 4.3 | +39.5% | ||
| 2025 | -2.4 | -13.5 | 3.8 | 73.5 | 11.6 | 0.4 | 20.3 | 17.4 | 11.5 | 6.2 | -32.3 | -23.0 | +48.3% |
| 2024 | 8.0 | 4.7 | -29.3 | -12.9 | 40.8 | -6.7 | 7.1 | 52.8 | 3.7 | -21.4 | 63.4 | 3.3 | +106.0% |
| 2023 | 18.3 | -10.2 | -4.7 | 4.5 | 18.5 | -3.7 | -15.2 | 2.4 | -4.0 | -29.3 | 7.6 | 8.2 | −17.1% |
| 2022 | -15.5 | -22.7 | 5.7 | -24.0 | -18.0 | 14.8 | 28.7 | -38.7 | -40.2 | -9.6 | 10.2 | -11.1 | −79.4% |
| 2021 | 18.9 | 16.5 | -4.3 | -3.7 | -15.5 | 5.2 | -20.5 | 18.3 | -3.5 | -14.6 | -11.5 | 13.1 | −11.9% |
| 2020 | -18.7 | -17.3 | -6.7 | -2.1 | -25.7 | 7.1 | 0.3 | 15.8 | -24.8 | 31.5 | 4.2 | -11.2 | −48.0% |
| 2019 | -2.8 | 18.5 | 42.4 | +64.0% |
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Buy / hold / sell counts